Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Horsmans, Y*" or (type exact bookEditor and editor="Horsmans, Y*")

Add to list
- Journal Article
- A1
- open access
Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital

Sylvie Goletti, Siméon Zuyten, Léonie Goeminne, Chris Verhofstede (UGent) , Hector Rodriguez-Villalobos, Monique Bodeus, Peter Stärkel, Yves Horsmans and Benoît Kabamba-Mukadi

(2019) BMC INFECTIOUS DISEASES. 19(1).
Add to list
- Journal Article
- A1
Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis

G. Muyldermans, R. Bielen, Ruth Botterman (UGent) , S. Bourgeois, I Colle, B. Deressa, G. Devolder, Y. Horsmans, V Hutse, N. Lanthier, et al.

(2019) ACTA GASTRO-ENTEROLOGICA BELGICA. 82(4). p.479-485
Add to list
- Journal Article
- A1
Pharmacokinetic interactions between simeprevir and ledipasvir in treatment naive hepatitis C virus genotype 1-Infected patients without cirrhosis treated with a simeprevir-sofosbuvir-ledipasvir regimen

Stefan Bourgeois, Yves Horsmans, Frederik Nevens, Hans Van Vlierberghe (UGent) , Christophe Moreno, Maria Beumont, Leen Vijgen, Veerle van Eygen, Donghan Luo, Vera Hillewaert, et al.

(2017) ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 61(12).
Add to list
- Journal Article
- A1
- open access
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

Stefan Bourgeois, Hans Van Vlierberghe (UGent) , Christophe Moreno, Hans Orlent, Frederik Nevens, Keikawus Arastéh, Yves Horsmans, Jörn M Schattenberg, Peter Buggisch, Sven Francque, et al.

(2017) BMC GASTROENTEROLOGY. 17.
Add to list
- Journal Article
- A1
- open access
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients : results from the GUARD-C cohort

Graham R. Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K. Rajender Reddy, Ludovico Tallarico, Mitchell L. Shiffman, Silke Ahlers, Georgios Bakalos, et al.

(2016) PLOS ONE. 11(3).
Add to list
- Journal Article
- A1
- open access
Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine : results from a phase II, randomized, multicenter trial

Geert Leroux-Roels (UGent) , Arnaud Marchant, Jack Levy, Pierre Van Damme, Tino F Schwarz, Yves Horsmans, Wolfgang Jilg, Peter G Kremsner, Edwige Haelterman, Frédéric Clement (UGent) , et al.

(2016) CLINICAL IMMUNOLOGY. 169. p.16-27
Add to list
- Journal Article
- A1
- open access
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

Geert Leroux-Roels (UGent) , Pascale Van Belle, Pierre Vandepapeliere, Yves Horsmans, Michel Janssens, Isabelle Carletti, Nathalie Garçon, Martine Wettendorff and Marcelle Van Mechelen

(2015) VACCINE. 33(8). p.1084-1091
Add to list
- Journal Article
- A1
Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials

Isabel Leroux-Roels (UGent) , Jeanne-Marie Devaster, Geert Leroux-Roels (UGent) , Vincent Verlant, Isabelle Henckaerts, Philippe Moris, Philippe Hermand, Pascale Van Belle, Jan T Poolman, Pierre Vandepapeliére, et al.

(2015) VACCINE. 33(4). p.577-584
Add to list
- Journal Article
- A1
Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium : a sub-analysis of the PROPHESYS study

J. P. Mulkay, S. Bourgeois, L. Lasser, C. De Galocsy, S. Tomasovic, Y. Horsmans and Hans Van Vlierberghe (UGent)

(2014) ACTA GASTRO-ENTEROLOGICA BELGICA. 77(1). p.30-40
Add to list
- Journal Article
- A1
Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients

Olivier Dewit, Tom Moreels, Filip Baert, Harald Peeters (UGent) , Catherine Reenaers, Martine De Vos (UGent) , Ph Van Hootegem, V Muls, G Veereman, F Mana, et al.

(2011) CLINICAL BIOCHEMISTRY. 44(13). p.1062-1066
Add to list
- Journal Article
- A1
- open access
Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust Study

Hans Van Vlierberghe (UGent) , M Adler, B Bastens, Isabelle Colle (UGent) , J Delwaide, J Henrion, Y Horsmans, P Michielsen, P Golstein, JP Mulkays, et al.

(2010) ACTA GASTRO-ENTEROLOGICA BELGICA. 73(1). p.5-11
Add to list
- Journal Article
- A1
- open access
Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat

Meng Fang (UGent) , Sylviane Dewaele (UGent) , Yun-peng Zhao, Peter Starkel, Valerie Vanhooren (UGent) , Yue-ming Chen, Xin Ji, Ming Luo, Bao-mu Sun, Yves Horsmans, et al.

(2010) MOLECULAR CANCER. 9.
Add to list
- Journal Article
- A1
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naive or relapsing chronic hepatitis C patients

P. Langlet, F D'Heygere, J Henrion, M Adler, J Delwaide, Hans Van Vlierberghe (UGent) , JP Mulkay, L Lasser, R Brenard, Y Horsmans, et al.

(2009) ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 30(4). p.352-363
Add to list
- Journal Article
- A1
Weekly Pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection

Y Horsmans, Isabelle Colle (UGent) , Hans Van Vlierberghe (UGent) , P Langlet, M Adler, N Bourgeois, R Brenard, P Michielsen, A Goossens and L Bruckers

(2008) ACTA GASTRO-ENTEROLOGICA BELGICA. 71(3). p.293-297
Add to list
- Journal Article
- A1
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

Pierre Vandepapeliere, Yves Horsmans, Philippe Moris, Marcelle Van Mechelen, Michel Janssens, Marguerite Koutsoukos, Pascale Van Belle, Frédéric Clement (UGent) , Emmanuel Hanon, Martine Wettendorff, et al.

(2008) VACCINE. 26(10). p.1375-1386
Add to list
- Journal Article
- A1
A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C

S GERKENS, M NECHELPUT, Lieven Annemans (UGent) , B PERAUX, M MOUCHART, C BEGUIN and Y HORSMANS

(2007) JOURNAL OF VIRAL HEPATITIS. 14(8). p.523-536
Add to list
- Journal Article
- A1
A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels

S GERKENS, M NECHELPUT, Lieven Annemans (UGent) , B PERAUX, C BEGUIN and Y HORSMANS

(2007) ACTA GASTRO-ENTEROLOGICA BELGICA. 70(2). p.177-187
Add to list
- Journal Article
- A1
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

P VANDEPAPELIERE, GKK LAU, Geert Leroux-Roels (UGent) , Y HORSMANS, E GANE, T TAWANDEE, MI BIN MERICAN, KM WIN, C TREPO, G COOKSLEY, et al.

(2007) VACCINE. 25(51). p.8585-8597
Add to list
- Journal Article
- A1
Oral fluid as a medium for the detection of hepatitis B surface antigen

Veronik Hutse, Els Verhaegen, Liesbet De Cock, Sophie Quoilin, Hans Vandenberghe, Yves Horsmans, Peter Michielsen, Pierre Van Damme, Hans Van Vlierberghe (UGent) , Françoise Claeys, et al.

(2005) JOURNAL OF MEDICAL VIROLOGY. 77(1). p.53-56
Add to list
- Conference Paper
- C3
Improvement in liver histology after 3 years of E1 therapeutic vaccination in 23 patients with chronic hepatitis C

F NEVENS, T ROSKAMS, Hans Van Vlierberghe (UGent) , Y HORSMANS, D SPRENGERS, A ELEWAUT, V DESMET, Geert Leroux-Roels (UGent) , A DE BRAUWER, E DEPLA, et al.

(2004) HEPATOLOGY. 40(4).
Add to list
- Miscellaneous
Hepatitis C: Screening, treatment and prevention practical guidelines

P MICHIELSEN, R BRENARD, N BOURGEOIS, C DE GALOCSY, J DELWAIDE, J HENRION, Y HORSMANS, F NEVENS, H REYNAERT, G ROBAEYS, et al.

(2003) ACTA GASTRO-ENTEROLOGICA BELGICA. 66(1). p.15-19
Add to list
- Journal Article
- A1
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C

F NEVENS, T ROSKAMS, Hans Van Vlierberghe (UGent) , Y HORSMANS, D SPRENGERS, A ELEWAUT, V DESMET, Geert Leroux-Roels (UGent) , E QUINAUX, E DEPLA, et al.

(2003) HEPATOLOGY. 38(5). p.1289-1296
Add to list
- Journal Article
- A1
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial

Hans Van Vlierberghe (UGent) , Geert Leroux-Roels (UGent) , M ADLER, N BOURGEOIS, F NEVENS, Y HORSMANS, J BROUWER, Isabelle Colle (UGent) , J DELWAIDE, R BRENARD, et al.

(2003) JOURNAL OF VIRAL HEPATITIS. 10(6). p.460-466
Add to list
- Journal Article
- A1
Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients

Hans Van Vlierberghe (UGent) , Michel Langlois (UGent) , Joris Delanghe (UGent) , Y HORSMANS, P MICHIELSEN, J HENRION, R CARTUYVELS, J BILLIET, Martine De Vos (UGent) and Geert Leroux-Roels (UGent)

(2001) JOURNAL OF HEPATOLOGY. 35(6). p.707-711
Add to list
- Miscellaneous
Chronic hepatitis B therapy with lamivudine in clinical practice - Summary of the discussion

J DIXON, J DELWAIDE, Y HORSMANS and Hans Van Vlierberghe (UGent)

(2000) ACTA GASTRO-ENTEROLOGICA BELGICA. 63(4). p.357-358
Add to list
- Journal Article
- A1
HLA association of amoxicillin-clavulanate-induced hepatitis.

Marc Hautekeete, Y HORSMANS, C VAN WAEYENBERGE, C DEMANET, J HENRION, L VERBIST, R BRENARD, C SEMPOUX, PP MICHIELSEN, PSH YAP, et al.

(1999) GASTROENTEROLOGY. 117(5). p.1181-1186

Academic Bibliography

Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital

Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis

Pharmacokinetic interactions between simeprevir and ledipasvir in treatment naive hepatitis C virus genotype 1-Infected patients without cirrhosis treated with a simeprevir-sofosbuvir-ledipasvir regimen

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients : results from the GUARD-C cohort

Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine : results from a phase II, randomized, multicenter trial

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials

Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium : a sub-analysis of the PROPHESYS study

Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients

Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust Study

Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat

Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naive or relapsing chronic hepatitis C patients

Weekly Pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C

A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

Oral fluid as a medium for the detection of hepatitis B surface antigen

Improvement in liver histology after 3 years of E1 therapeutic vaccination in 23 patients with chronic hepatitis C

Hepatitis C: Screening, treatment and prevention practical guidelines

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C

Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial

Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients

Chronic hepatitis B therapy with lamivudine in clinical practice - Summary of the discussion

HLA association of amoxicillin-clavulanate-induced hepatitis.

Contents

Support

Contact